Pembrolizumab (MK-3475)
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for Pembrolizumab (MK-3475), covering 2025-05-30 to 2026-04-20. Get the full timeline:
Most recent: Clinical Trial Update: A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) [Phase 3]